Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
adult, MDS, Research, Translational Research, Chronic Myeloid Malignancies, Diseases, Myeloid Malignancies, Study Population, Human
Methods: We retrospectively included all MDS patients followed in our center (Saint-Louis Hospital, Paris, France) between January 2015 and January 2022 with a molecular evaluation. According to the local laboratory threshold, lymphopenia was defined as ALC <1.5 G/L. Low (LR), intermediate (IR), and high-risk (HR) MDS were defined according to IPSS-M (LR: IPSS-M Low and Very Low, scores < -0.5; IR: IPSS-M Moderate Low and Moderate High, scores -0.5 to 0.5; and HR: IPSS-M High and Very High, scores >0.5 respectively). Survival analyses were estimated between MDS diagnosis until death from any cause (OS) or last follow-up, or until AML transformation (LFS) or last follow-up. Allogeneic stem cell transplantation was considered a censoring event.
Results: Our cohort included 372 MDS patients (45% females, median age 72 IQR[65-79]) with 230 (62%), 70 (19%), and 72 (19%) patients with LR, IR and HR-MDS respectively. Compared to IPSS-R, molecular IPSS reclassified 175 patients (47%, with 97 (26%) upstaged and 78 (21%) downstaged). The median ALC in the whole cohort was 1.20 IQR[0.87-1.60] G/L. Lymphopenia was highly prevalent in all MDS subgroups (68%, 79% and 75% in LR, IR and HR-MDS respectively), and ALC inversely correlated with higher IPSS-M (Spearman rho=-0.13, p=0.01).
Lymphopenia was associated with lower ANC (median 1.90 IQR[1.1-3.4] versus 2.70 IQR[1.6-4.2], p=0.01) and monocyte count (median 0.31 IQR[0.17-0.46] versus 0.42 IQR[0.25-0.78], p=0.04). Lymphopenia was not significantly associated with an excess of marrow blasts (78/267, 29% versus 21/105, 21% in patients with or without lymphopenia respectively, p=0.09). However, its prevalence was significantly lower in MDS with ringed sideroblasts (RS) (27/49 (55%) versus 240/267 (90%), p<0.01). Consistently, SF3B1 mutations were more prevalent in MDS patients without lymphopenia (29/107 (27%) versus 27/265 (10%), p<0.01), while the rest of the somatic mutational landscape did not differ between the 2 groups.
The median follow-up of the entire cohort was 4.1 IQR[3.7-4.6] years. Among IPSS-M categories, lymphopenia adversely impacted OS and LFS in LR-MDS patients (median 8.8 years vs not reached for OS, p=0.02; median 12.3 years versus not reached, p=0.02 for LFS) but not in IR (p=0.34 and p=0.49 for OS and LFS respectively) or in HR-MDS (p=0.82 and p=0.83) patients (Figure 1). In SF3B1 mutated LR-MDS patients (n=46), the adverse prognostic impact of lymphopenia at diagnosis was still significant for both OS (p=0.03) and LFS (p=0.03).
Conclusion: In this single-center retrospective analysis, lymphopenia was highly prevalent at MDS diagnosis in all IPSS-M subgroups and ALC negatively correlated with disease severity. The presence of lymphopenia adversely impacted OS and LFS in the LR-MDS subgroup, potentially suggesting a significant role of host immunity in early disease phase and possibly adding a prognostic parameter to IPSS-M.
Disclosures: Sebert: Abbvie: Honoraria; Servier: Honoraria, Research Funding; BMS: Honoraria; Gilead: Honoraria; Jazz Pharmaceuticals: Honoraria. Fenaux: Novartis: Consultancy, Honoraria, Research Funding; Jazz: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; French MDS Group: Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding.
See more of: Oral and Poster Abstracts